Insulet Revenue Growth Rates (PODD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Insulet Corporation  (NASDAQ: PODD)
 

PODD's Revenue Growth by Quarter and Year

Insulet's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PODD/growth
https://api.csimarket.com/api/v1/companies/PODD/fundamentals
https://api.csimarket.com/api/v1/companies/PODD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PODD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 842.00
2nd Quarter June 801.70
1st Quarter March 761.70
FY 2,405.40

PODDs Annual Revenue
Insulet's Revenue in the fiscal year 2025 $ 2,708.10 millions
Insulet's Revenue in the fiscal year 2024 $ 2,071.60 millions
Insulet's Revenue in the fiscal year 2023 $ 1,697.10 millions
Insulet's Revenue in the fiscal year 2022 $ 1,305.30 millions
Insulet's Revenue in the fiscal year 2021 $ 1,098.80 millions




PODD Revenue third quarter 2026 Y/Y Growth Comment
Insulet Corporation reported Revenue increase of 19.21% year on year in the third quarter 2026, to $ 842.00 millions, this is lower than Insulet Corporation's recent average Revenue improvement of 26.27%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 53 other companies have achieved higher Revenue growth. While Insulet Corporation' s Revenue growth of 19.21% ranks overall at the positon no. 911 in the third quarter 2026.


PODD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 19.21 %
2nd Quarter June 23.51 %
1st Quarter March 33.87 %
FY   -

Financial Statements
Insulet's third quarter 2026 Revenue $ 842.00 millions PODD's Income Statement
Insulet's third quarter 2025 Revenue $ 706.30 millions Quarterly PODD's Income Statement


PODD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.03 %
2nd Quarter June 5.25 %
1st Quarter March -2.81 %
FY (Year on Year)   -


Back to PODD Growth rate Comparisons >> Back to PODD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #188
Overall #911

Revenue Y/Y Growth Statistics
High Average Low
75.19 % 26.27 % -30.38 %
(Jun 30 2012)   (Sep 30 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #188
Overall #911
Revenue Y/Y Growth Statistics
High Average Low
75.19 % 26.27 % -30.38 %
(Jun 30 2012)   (Sep 30 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Insulet's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
38.44 % 6.19 % -22.17 %
(Sep 30 2011)  


PODD's III. Quarter Q/Q Revenue Comment
Insulet Corporation achieved in the III. Quarter 2026 below company average Revenue increase of 5.03% quarter on quarter, to $ 842.00 millions.

Within Medical Equipment & Supplies industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Insulet's Revenue growth quarter on quarter, overall rank is 1140.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #46
Healthcare Sector #166
Overall #1140
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #46
Healthcare Sector #166
Overall #1140
Revenue Q/Q Growth Statistics
High Average Low
38.44 % 6.19 % -22.17 %
(Sep 30 2011)  


PODD's III. Quarter Q/Q Revenue Comment
Insulet Corporation achieved in the III. Quarter 2026 below company average Revenue increase of 5.03% quarter on quarter, to $ 842.00 millions.

Within Medical Equipment & Supplies industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Insulet's Revenue growth quarter on quarter, overall rank is 1140.


Insulet's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3,053.40
Y / Y Revenue Growth (TTM) 29.41 %
Year on Year Revenue Growth Overall Ranking # 660
Seqeuential Revenue Change (TTM) 5.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 1799


Cumulative Revenue growth Comment
Assuming the Insulet's fiscal year would have ended in Jun 30 2026, Insulet would have reprted above average annual Revenue rise of 29.41% year on year, of $ 3,053 millions.
This marks a slow-down of the companys growth trends and from the 31.92% improvement in Mar 31 2026.

In the Healthcare sector 136 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 576 to 660.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 106
Healthcare Sector # 137
Overall # 660

Revenue TTM Y/Y Growth Statistics
High Average Low
67.63 %
 25.22 %
-16.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 285
S&P 500 # 1799
Cumulative Revenue growth Comment
Assuming the Insulet's fiscal year would have ended in Jun 30 2026, Insulet would have reprted above average annual Revenue rise of 29.41% year on year, of $ 3,053 millions.
This marks a slow-down of the companys growth trends and from the 31.92% improvement in Mar 31 2026.

In the Healthcare sector 136 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 576 to 660.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 106
Healthcare Sector # 137
Overall # 660

Revenue TTM Y/Y Growth Statistics
High Average Low
67.63 %
25.22 %
-16.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 285
S&P 500 # 1799




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PODD's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions


About Insulet Revenue Growth Rates (PODD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Insulet Corp (CIK 1145197).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001145197-26-000192
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Insulet Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.